Ariad Pharmaceuticals Inc fka ARIA

[Whosetosay]

Your post has no surprises. It has no detail except sweeping, unsubstantiated comments.

My post was about LUMA articles. What specifically is wrong with my comments, and what in those articles, apart from what I mentioned, did you find so freshly positive?

The only reasonable part of the articles was they confirmed our first and last line label for CML T315I in chronic phase, something we already knew and have approval for, but that the company truly underserves, and as folks listens to the Q calls or AGMs, knows that Ariad trys to avoid Pona being just a T315I medicine.

So, what did you see so wildly positive in those 2 pieces? Radotinib (another TKI approved now in ASIA) or T315I, Pona vs. BMT C,A,B?

I look forward to your many specific points on those.

As for Denner, it's nice of him to wait until our market cap is the lowest it has been in 2 years since the crash to put the 'for sale' sign in the window. What ever happened to 'sell high'? It's 5X from here to get to your target in the 20's.